Zee’s Punit Goenka pays Rs 50 lakh to settle insider trading case
时间:2024-06-02 02:29:59 阅读(143)
Punit Goenka, MD and CEO of Zee Entertainment (ZEEL), has paid Rs 50 lakh to settle the insider trading case related to shares of Zee, according to a Sebi announcement on Thursday.
The regulator had, in August last year, passed an interim order against 15 entities for carrying out insider trading activities with respect to the Zee scrip. Confirmatory orders for the same were passed in September last year and February this year.
The firm had launched cinema-to-home service ZEEPLEX in 2020, a pay-per-view service and “new content consumption medium for consumers and film distribution model”.
Sebi’s investigation concluded that announcement of the launch of ZEEPLEX amid Covid restrictions qualified as ‘expansion of business’, and was thus a positive development about the company. Information related to business expansion is covered under regulations pertaining to UPSI.
The Prohibition of Insider Trading (PIT) Regulations, 2015, state that the MD, CEO, and the likes in listed companies shall put in place an adequate and effective system of internal controls to put a check on insider trading and to ensure compliance with the stated regulations.
However, the regulator found that Goenka — who was MD and CEO during ZEEPLEX’s launch — failed to put in place adequate internal controls to identify UPSI, and failed to classify the said information as UPSI.
As a result, the regulator issued a show cause notice to Goenka in December 2022. Goenka subsequently agreed to settle the matter “without admitting or denying the findings of fact and conclusions of law”.
上一篇:Sugar price climbs to fresh six-year high in US as limited India exports adds to supply worries
下一篇:Women-led development, by India’s women-led enterprises – a key piece of $5 trillion goal
猜你喜欢
- Rupee rises 4 paise to close at 82
- Rupee rises 2 paise to 83
- Tata group stock gearing for gains, charts show; share price may rally 14% in 3 months
- Rupee rises 2 paise to close at 83
- Samsung Galaxy S24 series leaks are getting out of hand; here’s everything we know so far
- Rupee may depreciate this week amid pessimistic market sentiments, firm dollar; USDINR to trade in this range
- Sun Pharmaceuticals rating – Buy- One-offs hit bottomline in Q4FY22
- Rupee to appreciate further amid soft dollar, rise in risk appetite; dollar index may decline till 100
- Rupee recovers 6 paise to settle at 82